Form 4: OnKure Therapeutics Chief Medical Officer Granted Stock Options

OnKure Therapeutics' Chief Medical Officer, Samuel Agresta, was granted 45,000 stock options on January 27, 2025, which vest monthly over four years.

Summary

• Samuel Agresta, the Chief Medical Officer of OnKure Therapeutics, was granted 45,000 employee stock options on January 27, 2025.
• The exercise price of these options is $5.19 per share.
• The options vest monthly, with 1/48th of the shares vesting each month starting February 27, 2025, provided Mr. Agresta remains a service provider.
• The options expire on January 26, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If Mr. Agresta leaves the company before the options fully vest, he may forfeit some or all of the unvested options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 1/48th monthly is a typical vesting schedule for stock options.
• The exercise price of $5.19 is specific to OnKure's stock price at the time of the grant.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the Chief Medical Officer to work towards increasing the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, OnKure Therapeutics, Samuel Agresta, vesting